‘Aspirin’ can be an effective medication for the women as an inexpensive lung cancer chemoprevention though causing few side effects. A recent research study findings give a clear indication with clinical evidences.
This specific case-control study involved almost 581 African-American and Caucasian women with and without’ non-small-cell lung cancer (NSCLC)’. Findings of the study revealed that the regular use of aspirin helps in reducing the risk for the disease by a significant 34% rate among women.
Certain previous specific research studies also indicated that aspirin and other similar ‘non-steroidal anti-inflammatory drugs (NSAIDs)’ have potential for decreasing the risk for NSCLC. Some of the other studies however, established that the results of this degree are not quite possible.
Researchers are of the view that even in the case of the poor 5-year survival rate among the lung cancer patients it becomes quite imperative to find a ray of hope for preventing the lung cancer risks. At present there exists no specific effective know method for preventing ling cancer other than the established smoking cessation.
Participants of this research study belonged to a wide ranging age group of 18 to 74 years. Between the period of the year 2001 November, and 2005 October, all these participants were diagnosed with primary NSCLC. They were also compared with 541 population-based controls.
Van Dyke and co-researchers observed that there was a reduction in the risk for NSCLC when the factors were adjusted accordingly. These factors included body mass index (BMI), family history of lung cancer, history of chronic obstructive lung disease, arthritis, and cardiovascular disease. It was also observed that the level of protection increased significantly with duration of use.
Stratified analyses of the results obtained in this study indicate that the reduction in NSCLC with regular use of aspirin was confined to Caucasian women with an odds ratio of 0.63. This ratio was measured to be 0.43 in the case of women who were in an age group of 55-64 years.
Researchers found that the adjustments on the similar lines with regular use of baby aspirin, acetaminophen, and NSAIDs were not significantly associated with the risk for lung cancer in adjusted analyses. Stratified analyses however, revealed a significant 47% reduction in the risk for lung cancer with baby aspirin. There was a similar reduction of 59% with the use of NSAIDS in case of the women who belonged to the age group of 65-74 years.
Researchers concluded in their study, “Our results suggest that long-term use of adult strength aspirin may reduce risk of NSCLC among women”.
News published in CoolHealthTips.com are unique and property of the site only. Copying Contents or Publishing any News from CoolHealthTips.com is strictly not allowed and against Site’s policy.